Forum Topic Pharmaceutical
  • Conversation: Moleculin Announces Completion of Lymphoma Trial Enrollment

    • August 13, 2019 9:16 PM BST
      • Post(s)

      Moleculin Announces Completion of Lymphoma Trial Enrollment

      Moleculin Biotech, Inc., a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced its proof of concept clinical trial to evaluate its p-STAT3 inhibitor, WP1220, for the topical treatment of Cutaneous T-Cell Lymphoma (CTCL) has reached full enrollment.
      "We believe there continues to be an unmet need for an improved topical therapy for Stage I-III CTCL skin lesions," commented Walter Klemp, Moleculin's Chairman and CEO, "especially one that may avoid significant unwanted side effects. CTCL is known to frequently involve the upregulation of the activated form of STAT3 (p-STAT3), which has been linked to a range of tumor-related transcriptional activity.
      Read more:

Add Reputation

Do you want to add reputation for this member by this post?

or cancel